Search Results - paul+boutros

7 Results

Sort By:

Urine-Based Diagnostics for Prostate Cancer (UCLA Case No. 2023-302)

UCLA researchers in the Department of Human Genetics have developed a urine-based method for non-invasive prostate cancer diagnosis. By quantifying secreted and extracellular vesicles proteomes from urine, they identified protein biomarkers that enable accurate diagnosis and risk stratification of prostate cancer, outperforming the current PSA test. BACKGROUND:...

Published: 11/5/2024 | Inventor(s): Paul Boutros

Keywords(s): biomarkers, Cancer, diagnostics, extracellular vesicle, genitourinary, prostate cancer, prostatic lesion, risk stratification, secreted proteome, urinary proteome, Urine-based

Category(s): Diagnostic Markers

2021-319 GENOMIC COPY NUMBER ABERRATIONS IN ZNRF3 AS PROGNOSTIC AND PREDICTIVE BIOMARKERS FOR LOCALIZED PROSTATE CANCER

SUMMARY: Researchers from UCLA’s Departments of Human Genetics and Urology have identified a novel biomarker and actionable target for prostate cancer metastasis. BACKGROUND: Prostate cancer is one of the most commonly diagnosed cancers and the second leading cause of cancer death in men. Although most men present with localized, potentially...

Published: 9/25/2024 | Inventor(s): Michael Fraser, Paul Boutros

Keywords(s):

Category(s): Diagnostic Markers, Therapeutics > Oncology

Germline Determinants of the Prostate Tumor Genome (UCLA Case No. 2021-201)

SUMMARY: Researchers from UCLA’s Departments of Human Genetics and Urology have developed a novel method to predict disease susceptibility and aggression of multiple hereditary cancer types in individuals which will inform more personalized and effective therapies. BACKGROUND: The American Cancer Society reports that approximately 40% of people...

Published: 8/29/2024 | Inventor(s): Paul Boutros, Kathleen Houlahan

Keywords(s):

Category(s): Diagnostic Markers, Therapeutics > Oncology

2020-182 MITOCHONDRIAL DNA PROSTATE CANCER MARKER AND RELATED SYSTEMS AND METHODS

Researchers in UCLA Department of Human Genetics have developed a novel method of using the mitochondrial genome of prostate cancer patients to predict which tumours are likely to become lethal.BACKGROUND:Prostate cancer remains the most prevalent non-skin cancer in men. Most studies of the prostate cancer genome focused on mutations in the nuclear...

Published: 7/19/2023 | Inventor(s): Paul Boutros, Robert Bristow

Keywords(s): Artifical Intelligence (Machine Learning, Data Mining), Bioinformatics, Diagnostic Markers & Platforms, Diagnostic Platform Technologies (E.G. Microfluidics), Life Science Research Tools, Oncology, Research Methods, Software, Software & Algorithms

Category(s): Life Science Research Tools > Research Methods, Platforms > Diagnostic Platform Technologies, Therapeutics > Oncology, Software & Algorithms > Bioinformatics, Software & Algorithms > Artificial Intelligence & Machine Learning, Software & Algorithms > Programs

2020-162 GERMLINE DETERMINANTS OF PROSTATE CANCER AGGRESSION

UCLA researchers in the Department of Human Genetics & Urology, have created a new statistical strategy to identify 1,178 new inherited biomarkers in treatment-naïve prostate cancer patients, that are able to predict how prostate cancer will progress.BACKGROUND: The Centers for Disease Control and Prevention estimate that new cancer diagnoses...

Published: 7/19/2023 | Inventor(s): Paul Boutros

Keywords(s): Diagnostic Markers & Platforms, Oncology

Category(s): Therapeutics > Oncology

2020-181 BIOPSY-DRIVEN GENOMIC SIGNATURE FOR PROSTATE CANCER PROGNOSIS

Researchers at UCLA and in Canada have developed a novel biopsy-driven genomic signature for prostate cancer prognosis.BACKGROUND:Prostate cancer is the second most common cause of male cancer deaths in North America. While most prostate cancers are indolent and are unlikely to cause, about 30% of men will experience an aggressive cancer that will recur...

Published: 7/19/2023 | Inventor(s): Paul Boutros, Robert Bristow

Keywords(s): Diagnostic Markers & Platforms, Oncology

Category(s): Therapeutics > Oncology

2020-183 CANCER RISK BASED ON TUMOUR CLONALITY

Researchers from the Ontario Institute for Cancer Research, the University Health Network, and the UCLA Department of Human Genetics have created a novel method to determine whether a cancer will be lethal or not based on tumor clonality. BACKGROUND:Cancer occurs from the accumulation of mutations within a cell that cause the cell to behave in an abnormal,...

Published: 7/19/2023 | Inventor(s): Shadrielle Melijah Espiritu, Paul Boutros

Keywords(s): Diagnostic Markers & Platforms, Oncology

Category(s): Therapeutics > Oncology